Mechanisms of atrial fibrillation in athletes: what we know and what we do not know. by Guasch i Casany, Eduard et al.
1 
 
 1 
 2 
Mechanisms of atrial fibrillation in athletes: what we known and what we do not 3 
know 4 
E. Guasch1; L. Mont1; M. Sitges1 5 
 6 
1) Institut Clinic Cardiovascular, Hospital Clínic de Barcelona; IDIBAPS; Universitat de 7 
Barcelona; CIBERCV. 08036 Barcelona, Catalonia (Spain). 8 
 9 
 10 
 11 
Short title: Exercise-induced AF 12 
 13 
 14 
 15 
  16 
2 
 
Abstract 1 
Exercise is an emerging cause of atrial fibrillation (AF) in young individuals without coexisting 2 
cardiovascular risk factors. The causes of exercise-induced atrial fibrillation remain largely 3 
unknown, and conclusions are jeopardised by apparently conflicting data. Some components of 4 
the athlete’s heart are known to be arrhythmogenic in other settings. Bradycardia, atrial 5 
dilatation and, possibly, atrial premature beats are therefore biologically plausible contributors 6 
to exercise-induced AF. Challenging findings in an animal model suggest that exercise might also 7 
prompt the development of atrial fibrosis, possibly due to cumulative minor structural damage 8 
after each exercise bout. However, there is very limited, indirect data supporting this hypothesis 9 
in athletes. Age, sex, the presence of comorbidities and cardiovascular risk factors, and genetic 10 
individual variability might serve to flag those athletes who are at the higher risk of exercise-11 
induced AF. In this review, we will critically address current knowledge on the mechanisms of 12 
exercise-induced AF. 13 
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1. Introduction 1 
Atrial fibrillation (AF) is the most frequently sustained arrhythmia in the developed 2 
world, bearing a poor quality of life and increasing the risk of stroke and mortality. AF 3 
prevalence has been steadily increasing in recent years, and the number of individuals 4 
with AF is expected to double by 2060 [1]. The main factors promoting AF are ageing, 5 
structural heart disease, hypertension and diabetes, but these are absent in up to 15% 6 
of AF patients. The cause of AF in these young patients with no cardiovascular conditions 7 
has been the focus of extensive research in recent years, and obstructive sleep apnoea, 8 
obesity, a tall stature and genetic predisposition have all been associated with increased 9 
risk of AF [2,3].  10 
Reports published at the end of the 1990’s suggested that veteran athletes are also at a 11 
higher-than-expected risk of AF [4,5]. Subsequent small [6] and large epidemiological 12 
studies including >1 million individuals [7] confirmed this association. Endurance 13 
training is now a well-accepted cause of AF [8]. Heavily trained athletes are, on average, 14 
at a 3- to 8-fold increased risk of AF [5,6] and its prevalence is as high as 15% in veteran 15 
elite athletes [9,10]. An intense physical activity history is reported by up to 60% of 16 
young patients with AF in the absence of any cardiopulmonary disease [2]. Exercise-17 
induced AF is usually diagnosed in middle-aged males who have been practicing very 18 
intense endurance sports (e.g., marathon running [6], cycling [10], cross-country skiing 19 
[11]) for years, in general >10 years [12]. Not uncommonly, AF is diagnosed some years 20 
after regular training has been discontinued [6]. Overall, these data challenge the notion 21 
that the benefits of physical activity have no appreciable limits [13].  22 
The emergence of exercise as a potential cause of AF is relatively novel, and its pathology 23 
and underlying mechanisms remain largely unknown. Few works have shed some light 24 
on the causes of exercise-induced AF, and  uncertainties are still prevailing in this field. 25 
Is AF only a marker of extreme physical adaptation or is it associated with a pathological 26 
substrate? If so, do we have any evidence in humans of a deleterious effect of physical 27 
activity on cardiac structures? Why does the healthy exercise become harmful? Could 28 
illicit performance-enhancing substances play any role? While clinical and 29 
epidemiological evidence for exercise-induced AF is compelling, there is little evidence 30 
for a deleterious effect in the left ventricle (LV): why do these cardiac chambers behave 31 
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so different? And, finally, why do only a few athletes develop AF? In this review, these 1 
issues will be critically reviewed on the basis of current evidence.  2 
 3 
2. Is exercise-induced AF an extreme form of physiological adaptation? 4 
Our knowledge of the substrate that sustains AF in athletes is poor, largely speculative, 5 
based on general notions of AF pathology and, in few cases, derived from clinically 6 
relevant animal models. In the classic and simple, but useful, Coumel’s triangle, an 7 
appropriate substrate, a predisposing modulator and a timely trigger are needed in 8 
variable proportions to initiate and maintain AF (Fig. 1). The currently available evidence 9 
for the potential contribution of each of these mechanisms in exercise-induced AF is 10 
summarised in Table 1. Interestingly, some of the classical components of the 11 
physiologic cardiac adaptation to regular physical activity (so-called athlete’s heart) have 12 
also been associated to AF pathology.  13 
On the one hand, atrial size is a well-recognised independent predictor of incident AF 14 
[14]. In experimental models, LA dilatation facilitates the instauration and perpetuation 15 
of AF even in the absence of myocardial fibrosis [15]. We still do not fully understand 16 
the mechanisms behind AF promotion in dilated atria, but disparities on conduction 17 
velocity throughout the LA probably contribute [15]. Conduction heterogeneity might 18 
be originated by cellular electrophysiological changes occurring at the cellular level in 19 
hypertrophied cardiomyocytes [16]. Moreover, atrial dilatation increases the atrial 20 
critical mass and facilitates the establishment of re-entrant electrical activity and AF 21 
[17]. On the other hand, atrial dilatation is a hallmark of the athlete’s heart [18]. Atrial 22 
dilatation results from the adaptation of the atria to regular training: both atria enlarge 23 
to accommodate the increased cardiac output requirements during exercise. However, 24 
the characteristics of atrial dilatation are not exhaustively known. It is currently 25 
unknown whether atrial geometry differs in athletes and in patients with a heart 26 
disease. Notably, at a similar degree of atrial dilatation, atrial function seems to be 27 
preserved in athletes, but not in patients with a structural heart disease [19]. 28 
 29 
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A slow heart rate is a common finding in well-trained individuals. For decades, 1 
bradycardia in athletes has been attributed to an imbalance in autonomic tone 2 
characterised by parasympathetic tone enhancement and sympathetic tone withdrawal. 3 
Parasympathetic tone shortens the atrial refractory period and thereby facilitates re-4 
entry and AF. Results in an animal model suggest that exercise enhances 5 
parasympathetic tone partially through an increased cardiac sensitivity to acetylcholine, 6 
an effect mediated by downregulation of regulators of G protein signalling (RGS) [20]. In 7 
this model, parasympathetic enhancement was central in the early stages of exercise-8 
induced AF pathology [20]. Notably, most AF relapses in athletes occur in vagally-9 
dominant situations such as during sleep or after meals [4]. Remarkable clinical 10 
implications may derive if parasympathetic tone is confirmed as a main driver of 11 
exercise-induced AF. For example, antiarrhythmic drugs with vagolytic properties (e.g., 12 
dysopiramide [8,21]) could be favoured over other options, and intracardiac autonomic 13 
ganglia could become a primary target in ablation procedures [22]. Conversely, 14 
adrenergic-mediated AF is less frequent in athletes [4]. Although the parasympathetic 15 
and sympathetic tone shorten atrial refractoriness to a similar extent, the more 16 
heterogeneous atrial parasympathetic innervation yields a larger arrhythmic 17 
susceptibility [23].  18 
The notion that parasympathetic tone enhancement is the sole cause of bradycardia in 19 
athletes has recently been disputed. D’Souza et al. elegantly demonstrated in mice that 20 
a reduction in intrinsic heart rate (i.e., changes in the sinus node function independent 21 
of autonomic regulation) through HCN4 downregulation governs bradycardia in trained 22 
individuals [24], thereby supporting conclusions from previous studies in athletes [25]. 23 
Moreover, the modification of the intrinsic properties of the sinus node is consistent 24 
with reports pointing to a high prevalence of sinus node disease and pacemaker 25 
requirement in athletes [10]. The increased atrial refractoriness dispersion during 26 
bradycardia might indeed link intrinsic heart rate reduction to exercise-induced AF 27 
pathology [26].  28 
It is likely that both autonomic tone-mediated remodelling and intrinsic heart rate-29 
mediated remodelling contribute to bradycardia in athletes, and that the balance 30 
between both factors change with training intensity and/or sport discipline [27]. In the 31 
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general population, either parasympathetic tone-driven bradycardia or intrinsic heart 1 
rate-driven bradycardia is associated with a higher risk of AF [28].  2 
In the general population, atrial premature beats may trigger AF events in the presence 3 
of other predisposing factors or, when very frequent, may be the main etiological factor. 4 
It has been postulated that endurance athletes present with a higher burden of atrial 5 
premature beats than sedentary individuals [18,29]. Nevertheless, it remains unknown 6 
whether such a mild increase is enough to significantly contribute to the AF burden in 7 
athletes. 8 
Both atrial enlargement and bradycardia are more evident in endurance sports athletes 9 
than in strength sports (e.g., weight-lifting) practitioners. In parallel, exercise-induced 10 
AF is far more frequent in endurance athletes. On this basis, some authors hypothesised 11 
that AF might be an extreme manifestation of the physiological athlete’s heart. 12 
However, recent results from our and other groups disputed this notion. Works in 13 
animal models suggested that atrial fibrosis, a clearly pathological hallmark, could 14 
contribute to exercise-induced AF pathology. Atrial fibrosis disrupts normal electrical 15 
conduction in the atrium and, possibly, interferes with myocyte-fibroblast electrical 16 
coupling, thereby facilitating the establishment of re-entries and, eventually, AF [30]. In 17 
a rat model, we first found that a 16-week intense training protocol increased AF-18 
inducibility in an electrophysiological test. In addition to atrial dilatation and an 19 
enhanced parasympathetic tone, we observed increased atrial interstitial fibrosis [20], a 20 
finding that has been subsequently confirmed by others [31]. Of note, both studies 21 
found a modest (≈60%) increase in atrial fibrosis [20,31], contrasting to much larger 22 
atrial fibrosis deposits in other pathologic settings known to be associated with AF such 23 
as left ventricular dysfunction or valve disease. In these conditions, atrial fibrosis 24 
increases up to 500% [32]. Although some experimental work suggests that exercise-25 
induced atrial fibrosis drives AF inducibility [31], it is also plausible that additional 26 
contributing factors should be present, at least in the early stages of exercise-induced 27 
AF.  28 
 29 
3. Do we have data on a pathological remodelling in humans? 30 
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The confirmation in humans of a pathologic substrate in intensively trained individuals 1 
is still pending; in particular, the need of invasive tests to assess atrial fibrosis hampers 2 
its confirmation in athletes. Atrial biopsies are an unrealistic approach to quantify 3 
myocardial fibrosis in apparently healthy individuals, and magnetic resonance 4 
techniques are still underdeveloped. Therefore, only indirect estimates are currently 5 
available.  6 
Results on plasmatic biomarkers are consistent with the presence of a profibrotic state 7 
in some trained individuals. Active or veteran athletes present with higher levels of pro-8 
fibrotic markers such as galectin-3 [33], ST2 [34], certain circulating pro-fibrotic 9 
microRNAs such as mir-21 [35] and collagen turnover peptides PICP, CITP and TIMP-1 10 
[36]. These plasmatic biomarkers have been associated with incident or recurrent AF in 11 
clinical works in the general population and in patients with structural heart disease [37–12 
40]. It should be noted, though, that the interpretation of these results is complex and, 13 
at best, suggest the existence of a pro-fibrotic systemic environment that could favour 14 
atrial fibrosis. 15 
Echocardiographic parameters like atrial strain have been used as surrogate markers for 16 
the degree of atrial fibrosis in patients undergoing mitral valve surgery [41]. However, 17 
the results in well-trained endurance athletes are conflicting [42,43]. 18 
The ECG is an easy, widely available tool that may be useful to provide a rough approach 19 
to atria structures. In patients with mitral valve disease, p-wave duration associates with 20 
atrial fibrosis and size [44,45], and flags those individuals at an increased risk of AF. 21 
Endurance athletes present with an accumulated physical activity-dependent p-wave 22 
prolongation [43,46]. In football players, such a prolongation is independent of atrial 23 
size, and thereby fibrosis evolves as a plausible underlying substrate [47]. 24 
 25 
4. What triggers a pathological remodelling? 26 
Secondary prevention trials [48] and observational studies assessing incident AF in older 27 
individuals or in individuals with a high burden of cardiovascular risk factors [49–51] 28 
demonstrate that low to moderate load of physical activity is safe and may even be 29 
antiarrhythmic. However, a high exercise load may promote AF in some individuals. 30 
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Overall, these findings depict a U-shaped relationship between exercise load and AF 1 
incidence [2,12]. It is unclear which are the determinants promoting the transition from 2 
safe exercise to the appearance of this cardiovascular complication. Chances are that 3 
atrial dilatation or bradycardia beyond a certain level in well-trained athletes facilitate 4 
AF. It is also possible, though speculative, that an increase in AF incidence associates 5 
with the establishment of atrial fibrosis.  6 
In this regard, the mechanisms behind the potential instauration of atrial fibrosis remain 7 
unknown. Fig. 2 summarises the factors that have been postulated to contribute to 8 
exercise-induced atrial fibrosis. It is possible that systemic or mechanic insults during 9 
strenuous exercise bouts inflict cumulative microstructural myocardial damage. As for 10 
the RV, it has been postulated that such damage was associated with incomplete 11 
recovery between exercise bouts, thereby leading to permanent damage to the atria.  12 
Pro-inflammatory insults and low-level inflammation have been associated with 13 
AF incidence in the general population [52]. Although regular physical activity has been 14 
demonstrated to yield a systemic chronic anti-inflammatory effect, each exercise bout 15 
disturbs the inflammatory balance and prompts a pro-inflammatory status. Intense 16 
exercise transiently increases neutrophil count and induces the release of pro-17 
inflammatory cytokines such as interleukin-6, interleukin-8, C-reactive protein and ST2 18 
[34,53–55]. Systemic inflammation may locally extend to the myocardium. In a 19 
swimming-based animal model, extenuating exercise bouts were associated with 20 
leukocyte infiltration [56]. Interestingly, local inflammation mediated by stretch-21 
activated tumour necrosis-alpha (TNF-α) seems to be critical in exercise-induced atrial 22 
fibrosis pathology [31]. In humans, a transient p-wave prolongation after ultra-distance 23 
races was observed independently of atrial size, leading the authors to postulate that 24 
transient inflammatory infiltration or oedema could cause such conduction disturbances 25 
[57]. Changes in plasma of TNF-α and interleukin-12p70 concentrations correlate to 26 
right ventricular dysfunction after ultra-distance races in well-trained athletes [54]. 27 
Oxidative stress, which has also been linked to an increased AF incidence [58], increases 28 
in a load-dependent way after exercise [59]. Several attempts have been undertaken to 29 
blunt the pro-inflammatory and oxidative status after strenuous exercise with 30 
nutritional supplements and drugs, yielding conflicting results on the systemic 31 
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inflammatory status [60,61], and showing no benefits on cardiac haemodynamic 1 
overload markers [62]. 2 
A transient increase of cardiac necrosis markers (e.g., troponin I or troponin T) after long 3 
distance races was reported some years ago and claimed to be a marker of cardiac 4 
necrosis during exercise. Plasmatic troponin levels were associated with right 5 
ventricular, but not left ventricular, transient dysfunction after strenuous exercise [63], 6 
but a worse outcome in those athletes with repetitive troponin elevation has not been 7 
demonstrated. Conversely, our current understanding of troponin release during long 8 
races involves a process of cardiomyocyte membrane permeabilisation rather than 9 
pathological ischaemia [64]. To date, repetitive myocardial ischaemia and necrosis 10 
cannot be established as a source of AF substrate. 11 
Each exercise bout involves a volume overload that superimposes a mechanical stress 12 
to which the thin atrial wall is particularly sensitive. Wall stress positively correlates with 13 
intracavitary pressure and size, and inversely with wall thickness. Atrial enlargement 14 
implies that wall stress is higher, according to Laplace’s law (Figure 2). Additionally, if 15 
the curvature of the atria changes (i.e., becoming more elliptic), wall stress might also 16 
increase (the flatter the wall, the higher the wall stress) [65]. Atrial natriuretic peptide 17 
(ANP) levels, a marker of atrial stretch, is increased at rest in athletes in comparison with 18 
healthy individuals [66,67]. Atrial pressure increases during exercise [31,68], further 19 
increasing wall stretch and prompting a subsequent deleterious remodelling. Such 20 
deleterious effects might be particularly notorious in a subset of athletes with dilated 21 
and dysfunctional atria [69]. Increasing loads of physical activity are associated with an 22 
acute, dose-dependent transient atrial dysfunction, which becomes severe after very 23 
intense and prolonged bouts [70]. As aforementioned, increased atrial wall stress has 24 
been shown to trigger TNF-mediated activation of local inflammation, eventually leading 25 
to atrial fibrosis in an animal model [31]. Blocking TNF-α did prevent from exercise-26 
induced atrial fibrosis and inducibility. Speculatively, hidden hypertension or 27 
hypertension during exercise bouts may further exacerbate this increase in atrial wall 28 
stress and accelerate it [71]. Overall, increased atrial wall stretch appears as an 29 
attractive trigger for a pathological remodelling after strenuous exercise, but definitive 30 
proofs remain elusive. 31 
10 
 
 1 
5. What makes the atrium different, why does it selectively affect the atrium? 2 
For a long time, research in sports cardiology focussed on the study of the LV adaptation 3 
to variable amounts of physical activity. It was convincingly demonstrated that LV 4 
adaptation to high loads of physical activity does not usually convey pathological 5 
stigmas. Proteomic studies emphasised the physiological LV remodelling in intensively-6 
trained animals [72], and some studies suggest that physical activity may even protect 7 
against ventricular arrhythmias [73,74]. However, the atria and right ventricle were 8 
scarcely studied. 9 
The recent advent of potentially deleterious effects of very high doses of physical activity 10 
has moved the focus towards the atria and the right ventricle [12]. The physiological 11 
remodelling of the LV contrasts with the identification of atrial and right ventricular 12 
arrhythmias in athletes. Morphological, functional and molecular differences between 13 
the LV and the right ventricle and both atria underlie a distinct response to high levels 14 
of physical activity [75].  15 
As described in the previous section, the morphology of the atrium makes it particularly 16 
vulnerable to haemodynamic disturbances. Haemodynamic overload promotes atrial 17 
dilatation and, subsequently, increases wall stretch. Conversely, the ability of the LV to 18 
respond to repetitive mechanical overload insults by thickening its myocardial walls 19 
enables the LV to maintain wall stretch within a non-deleterious range [75,76]. This adds 20 
to differences in the cellular and molecular characterisation of atria and ventricles. 21 
Indeed, atrial fibroblasts show an enhanced reactivity to pathological stimuli in 22 
comparison with ventricular fibroblasts [77], resulting in a remarkably larger atrial than 23 
ventricular fibrosis burden upon the instauration of non-ischaemic heart failure in 24 
animal models [78].  25 
Altogether, clinical outcomes, morphological characteristics and fibroblast reactivity 26 
data suggest that atria are more sensitive to the haemodynamic overload than the LV, 27 
potentially justifying that the atria are primarily affected by the deleterious 28 
consequences of strenuous physical activity [12]. 29 
 30 
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6. Are performance-enhancing drugs a plausible explanation for exercise-induced 1 
AF? 2 
Performance-enhancing drugs have been postulated to contribute to AF burden in 3 
athletes. Nevertheless, the obscure nature of doping hinders any robust conclusion and 4 
thereby this issue remains, at least, speculative. Available data from athletes who have 5 
been banned from competition suggest that the most commonly used substances in 6 
high-level endurance-trained athletes who aim to improve their performance are 7 
erythropoietin (EPO), anabolic-androgenic steroids (AAS), and stimulant and 8 
sympathomimetic drugs.  9 
Erythropoietin and its derivatives increase erythrocyte synthesis and oxygen supply to 10 
peripheral muscle, evolving as a tempting drug for endurance athletes. To date, 11 
however, there is no data reporting AF as a significant side effect of EPO.  12 
The use of AAS has been associated with AF in isolated case-reports [79]. In body-13 
builders, it has been recently shown that chronic anabolic steroid administration 14 
associates with a prolonged atrial electromechanical delay [80]. Atrial electromechanical 15 
delay predicts new-onset AF, likely reflecting underlying substrate abnormalities [81]. 16 
Sympathomimetic drugs, such as ephedrine and amphetamine derivates, are used as 17 
stimulants and might trigger AF; a specific form of apoptosis in myocardial biopsies 18 
termed eosinophilic bands have been associated with ephedrine intake [82]. 19 
Nevertheless, it should be noted that the use of performance-enhancing substances is 20 
not exclusive for long-distance, endurance sports. Rather, their use is also relatively 21 
common in bodybuilders and weight-lifters, although no reports demonstrating an 22 
increased risk of AF in these cohorts has been published. It should be acknowledged, 23 
though, that it is biologically plausible that the effect of performance-enhancing 24 
substances is boosted in those endurance athletes in whom both a larger chamber 25 
dilatation/fibrosis and parasympathetic tone enhancement occur.  26 
 27 
7. Why do only some athletes develop AF?  28 
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While exercise is performed by a large part of the population, only some athletes will 1 
develop AF. Moreover, some individuals may get protected by exercise from AF, as 2 
aforementioned [48–51]. Fig. 3 summarises the factors involved in this complex 3 
relationship. In terms of AF incidence, the arrhythmogenicity of exercise likely results 4 
from the net balance between its beneficial (e.g., improvement of risk factors burden) 5 
and its potentially pro-arrhythmic (e.g., fibrosis) effects; age and the presence of 6 
cardiovascular risk factors modulate this relationship [12]. Elderly individuals accruing 7 
several cardiovascular risk factors may benefit from exercise [51]. Conversely, middle-8 
aged individuals without cardiovascular risk factors may be more prone to exercise-9 
induced AF [7]. 10 
On top of these factors, it is evident that some degree of genetically-derived 11 
interindividual variability facilitates the development of a pathological remodelling or 12 
enhance athlete’s heart features [69]. Men are apparently at a higher risk, likely because 13 
of bigger atria and a more extensive remodelling as compared with women [42]. 14 
Nevertheless, longer follow-up in contemporaneous cohorts of women is warranted 15 
[83]. The presence of certain genetic mutations or polymorphisms may put some 16 
athletes at a higher risk. A mutation in a subunit of the IKs potassium channel has been 17 
shown to confer an increased sensitivity to atrial stretch and could therefore facilitate 18 
AF during hypertension or in athletes [84]. Unfortunately, to date, data are insufficient 19 
to reliably identify those athletes who are at risk of exercise-induced AF. 20 
 21 
8. Conclusions 22 
The higher incidence of AF in athletes is now well-accepted, but its causes remain 23 
elusive. Atrial dilatation and parasympathetic enhancement are likely contributors. 24 
Some data in animals suggest that extreme physical activity associates with a 25 
pathological remodelling involving atrial fibrosis. Transient inflammation and increase 26 
in atrial wall stress, associated with uncomplete recovery, could trigger the 27 
development of atrial fibrosis. Nevertheless, confirmation in humans is still waiting, 28 
largely due to limitations in registries and histological confirmation. On the other hand, 29 
the contribution of performance-enhancing substances does not appear to be 30 
13 
 
remarkable. Overall, data are still insufficient to adopt specific prevention and diagnostic 1 
or prognostic strategies in the clinical setting. With our current knowledge, the potential 2 
risk of AF should not serve to limit physical activity load. 3 
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Figures 
 
Fig. 1 Schematic representation of the potential mechanisms underlying exercise-
induced atrial fibrillation represented in a Coumel’s triangle of arrhythmogenesis, and 
their functional consequences. 
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Fig. 2 Potential factors leading to a pathological atrial remodelling in athletes (atrial 
fibrosis). Systemic blood pressure and, particularly, pulmonary pressure promote an 
increase in atrial intracavitary pressure during exercise. In the presence of chronically 
dilated atria and limited ability to increase wall thickness, atrial wall stretch has 
remarkably increased, which may promote the activation of profibrotic mechanisms. A 
pro-inflammatory status during each exercise bout and intake of an illicit performance 
enhancer may also contribute. RA right atrium, LA left atrium. 
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Fig. 3 Representation of the factors contributing to the balance between the 
antiarrhythmic and the pro-arrhythmic effect of exercise. 
